09/975123

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE uction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Patent Number 6,750,019 B2 **TRANSMITTAL** Issue Date 06/15/2004 First Named Inventor **FORM** Susan M. Freier ANTISENSE MODULATION OF INSULIN-LIKE GROWTH Title FACTOR BINDING PROTEIN 5 EXPRESSION (to be used for all correspondence after initial filing) Attorney Docket Number RTS-0253 Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)										
		smittal Form		Drawing(s)  Licensing-related Papers			After Allowance Communication to TC  Appeal Communication to Board of Appeals and Interferences			
Amendment/Reply After Final Affidavits/declaration(s)  Extension of Time Request Express Abandonment Request Information Disclosure Statement  Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Rem	Petition Petition to Convert to a Provisional Application Power of Attorney, Revoca Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s)  Landscape Table on	e Address	Cert	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below): Certificate of Correction  Certificate NOV 0 4 2005  of Correction				
		SIGNA	TURE	OF APPLICANT, ATT	ORNEY, C	R AG	ENT			
Firm Name Isis Pharmaceuticals, Inc.										
Signature Council										
Printed	d name	Jodi L Connolly		<i>3</i>						
Date		10/26/05			Reg. No.	54,044				
CERTIFICATE OF TRANSMISSION/MAILING										

# I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Kemlyn Evans

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

the date shown below:

Typed or printed name

Signature

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

### UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.

: 6,750,019 B2

DATED

: 06/15/2004

INVENTOR(S) : Susan M. Freier

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

1) Title Page:

Item [56], References Cited, OTHER PUBLICATIONS, "Giorgio" reference, please delete "Pald" and insert therefor -- Palu' --:

2) Title Page:

Item [56], References Cited, OTHER PUBLICATIONS, "Miyakoski" reference, please delete "Miyakoski" and insert therefor -- Miyakoshi --:

3) Title Page:

Item [56], References Cited, OTHER PUBLICATIONS, "Rozen" reference, please delete "MCF T" and insert therefor -- MCF-7 -- :

4) Title Page:

Item [56], References Cited, OTHER PUBLICATIONS, "Rozen" reference, please delete "insulin like" and insert therefor -- insulin-like growth factor binding proteins, Int. J. Oncol., 1999, 15:589-594 --;

5) Title Page:

Item [56], References Cited, OTHER PUBLICATIONS, "Shamasaki" reference, please delete "Shamasaki" and insert therefor -- Shimasaki --;

6) Title Page:

Item [56], References Cited, OTHER PUBLICATIONS, "Beeh" reference, please delete "Beeh" and insert therefor -- Zeeh --:

#### MAILING ADDRESS OF SENDER:

PATENT NO. 6,750,019

Isis Pharmaceuticals, Inc. 1896 Rutherford Rd. Carlsbad, CA 92008

No. of additional copies

This collection of information is required by 37 CFR 1,322, 1,323, and 1,324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. And comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

: 6,750,019 B2 PATENT NO. DATED : 06/15/2004

INVENTOR(S) :

Susan M. Freier

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

7) Column 83, Claim 1, line 37, please delete the second occurrence of "nucleobases";

8) (	Column 83	Claim 1	, lines 52-53,	please delete	"oligonuclectide'	and insert therefor	oligonucleotide
------	-----------	---------	----------------	---------------	-------------------	---------------------	-----------------

#### MAILING ADDRESS OF SENDER:

PATENT NO. 6,750,019

Isis Pharmaceuticals, Inc. 1896 Rutherford Rd. Carlsbad, CA 92008

No. of additional copies

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.